LILLARD JAMES W has a total of 21 patent applications. Its first patent ever was published in 2007. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SPIROGENE PTY LTD, VISCUM AG and NEURO BIO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | China | 5 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Lillard James W | 21 |
#2 | Singh Shailesh | 20 |
#3 | Singh Rajesh | 17 |
#4 | Stiles Jonathan K | 3 |
#5 | Singh Udai P | 2 |
Publication | Filing date | Title |
---|---|---|
CN104066425A | Delivery system for specifically targeting cancer cells and method of use thereof | |
US2012100154A1 | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration | |
US2012100554A1 | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies | |
US2012135415A1 | Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies | |
US2012082993A1 | Detecting cancer with anti-cxcl16 and anti-cxcr6 antibodies | |
US2012128688A1 | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration | |
US2012064089A1 | Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration |